GeoVax to Release Third Quarter 2021 Financial Results on

0

The conference call will take place on Thursday, November 11 at 4:30 p.m. EST

ATLANTA, GA, November 04, 2021 (GLOBE NEWSWIRE) – via NewMediaWireGeoVax Labs, Inc. (Nasdaq: GOVX) (“GeoVax” or the “Company”), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, today announces that it will release its financial results for the third quarter of 2021 Thursday, November 11, 2021 after the market closes.

Management will hold a conference call at 4:30 p.m. ET on Thursday, November 11, 2021 to review the financial results and provide an update on the company’s developments. After formal management remarks, there will be a question-and-answer session.

Participants are invited to pre-register for the call via the following link:

https://dpregister.com/sreg/10161852/ef8e798f78

Please note that registered participants will receive their call number upon registration and will connect directly to the call without delay. Those who do not have internet access or cannot register can connect by dialing 1-866-777-2509 (national) or 1-412-317-5413 (international). All callers should dial approximately 10 minutes before the scheduled start time and request to be joined on the GeoVax Labs call.

The conference call will be available via a live webcast available here:

https://services.choruscall.com/mediaframe/webcast.html?webcastid=1oc5dy2h

A web replay of the call will be available through the same link as the live webcast approximately one hour after the call ends until February 11, 2022. A telephone replay of the call is available by calling 1- 877-344-7529 (domestic) or 1-412-317-0088 (international) and using the access code 10161852. The telephone replay will be available until November 25, 2021.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancer using new, patented platforms. GeoVax’s Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) vaccine platform uses MVA, a large virus capable of carrying multiple vaccine antigens, which expresses proteins that assemble into VLP immunogens in the person receiving the vaccine. The production of VLP in the vaccinated person can mimic the production of virus in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent and control the target infection. Vaccines derived from MVA-VLP can elicit long-lasting immune responses in the host similar to those of a live attenuated virus, while providing the safety characteristics of a replication-defective vector.

GeoVax’s MVA-VLP development programs focus on preventive vaccines against COVID-19, HIV, Zika virus and hemorrhagic fever viruses (Ebola, Sudan, Marburg and Lassa), as well as therapeutic vaccines against several cancers. The Company has designed a preventive HIV vaccine candidate to combat the HIV subtype prevalent in commercial markets in the Americas, Western Europe, Japan and Australia; Human clinical trials for this program are managed by the HIV Vaccine Trials Network (HVTN) with support from the National Institutes of Health (NIH). GeoVax’s HIV vaccine is also part of a collaborative effort towards a working cure for HIV.

In September 2021, GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of the exclusive rights to Gedeptin®, a new patented product for the treatment of solid tumors through a strategy of gene therapy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a non-human gene, which expresses an enzyme capable of converting a non-toxic prodrug into a highly toxic anti-tumor compound. A phase 1/2 trial is currently being enrolled to assess the safety and efficacy of repeated cycles of treatment with Gedeptin in patients with recurrent squamous cell carcinoma of the head and neck (HNSCC), with tumors accessible for injection and no curable treatment options. The initial phase of the study is funded by the FDA as part of its Orphan Product Clinical Trials Grants Program. A course of treatment with Gedeptin consists of three intra-tumor injections over a period of two days, followed by an infusion of a prodrug, fludarabine phosphate, once a day for three days. The FDA has granted orphan drug status to Gedeptin for the treatment of HNSCC. GeoVax’s license to Gedeptin includes the rights to extend its use to all human diseases and / or conditions, including, but not limited to, other cancers.

Caution Regarding Forward-Looking Statements

This press release and the related conference call contain forward-looking statements regarding GeoVax’s business plans and financial results. The words “believe”, “can”, “estimate”, “continue”, “anticipate”, “intend”, “should”, “plan”, “could”, “target”, “possible”, ” is probable ”,“ will ”,“ expect ”and similar expressions, as far as we are concerned, are intended to identify forward-looking statements. We have based these forward-looking statements in large part on our current expectations and projections regarding future events and financial trends that we believe could affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to various factors, including whether: GeoVax can develop and manufacture its vaccines with desired characteristics in a timely manner, GeoVax vaccines will be safe for human use, GeoVax vaccines prevent targeted infections in humans, GeoVax vaccines will receive the necessary regulatory approvals to be authorized and marketed, GeoVax is raising the capital required to complete vaccine development, there is the development of competitive products that can be more efficient or easier to use than GeoVax products, GeoVax will be able to secure favorable manufacturing and distribution agreements, the impact of the COVID-19 pandemic continues and other factors that GeoVax does not has no control.

Further information on our risk factors is contained in our registration statement on Form S-3 and periodic reports on Forms 10-Q and 10-K that we have filed and will file with the SEC. Any forward-looking statements we make here speak only as of the date on which they are made. Factors or events that could cause our actual results to vary may occur from time to time, and we cannot predict all of them. We assume no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

GeoVax Labs, Inc.
6783847220
[email protected]


Source link

Leave A Reply

Your email address will not be published.